Showing 1 - 2 results of 2 for search 'David Rageot', query time: 0.01s Refine Results
  1. 1
    Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour modelResearch in context

    Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a... by Carole Fournier, Marion Mercey-Ressejac, Valentin Derangère, Amal Al Kadi, David Rageot, Christine Charrat, Alexis Leroy, Julien Vollaire, Véronique Josserand, Marie Escudé, Séverine Escaich, François Ghiringhelli, Thomas Decaens, Fabrice P. Navarro, Evelyne Jouvin-Marche, Patrice N. Marche

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial

    Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial by Marion Thibaudin, Nicolas Roussot, Chloé Burlot, Antonin Schmitt, Julie Vincent, Zoé Tharin, Leila Bengrine, Hélène Bellio, Aurélie Bertaut, Léa Hampe, Susy Daumoine, Emilie Rederstorff, Morgane Peroz, Titouan Huppe, Valentin Derangère, David Rageot, John Simard, Caroline Truntzer, Jean David Fumet, Francois Ghiringhelli

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: